Home/Lexaria Bioscience/Gregory Downey

GD

Gregory Downey

Chief Financial Officer

Lexaria Bioscience

Therapeutic Areas

Cardiovascular Neurology Metabolic Disease Virology Smoking Cessation

Lexaria Bioscience Pipeline

Drug	Indication	Phase
DehydraTECH-CBD	Hypertension	Human Clinical
DehydraTECH-Nicotine	Smoking Cessation	Human Clinical
DehydraTECH for Antivirals	Viral Infections	Preclinical
DehydraTECH-sildenafil	Erectile Dysfunction	Human Clinical
DehydraTECH for GLP-1	Diabetes/Obesity	Research

Leadership Team at Lexaria Bioscience

Chief Executive Officer & Chairman

President & Director

View full Lexaria Bioscience profile